At #ObesityWeek2026, obesity expert Dr Angela Fitch discusses the evolving insurance landscape for #obesity medications and its impact on patient access to care.
https://t.co/pc4hVhyOZG
From #ObesityWeek2026, Dr Alaina Vidmar discusses the clinical and ethical considerations of prescribing #GLP1 therapies to metabolically healthy children.
https://t.co/7k5nTvdnmf
At #ObesityWeek2026, Dr Susan Phillips discusses a Phase 3 trial evaluating #setmelanotide for the treatment of acquired hypothalamic obesity.
https://t.co/1sohuCe86e
In #T2D, glucose is rarely isolated:
• 88% overweight/#obesity
• 76.4% hypertension
• 53.2% HbA1c ≥7%
• 32.2% inactive
What is the toughest clinic hurdle: therapeutic inertia or lifestyle adherence?
Full data: ➡️ https://t.co/RiMK1eRlpA
#MedTwitter#Type2Diabetes
John Batsis, MD, highlighted strategies for monitoring and preserving muscle function in older patients receiving #GLP1 receptor agonists at #ObesityWeek2026.
https://t.co/P9t9LEocJH
Researchers in a study discussed at #ObesityWeek2026 evaluated the efficacy and safety of lower doses of #cagrilintide plus #semaglutide in adults with overweight or #obesity.
https://t.co/TiSVINn0Ql
Researchers in a study discussed at #ObesityWeek2026 evaluated the impact of obesity-related conditions on work productivity and indirect costs among adults with overweight or #obesity.
https://t.co/heBHFXI2ZV
The SURMOUNT-ADOLESCENTS trial, presented at #ObesityWeek2026, evaluated the efficacy and safety of #tirzepatide in adolescents with #obesity and weight-related conditions.
https://t.co/PWbeYQqBpq
Researchers evaluated real-world dose escalation trajectories for #semaglutide and #tirzepatide in chronic weight management in a study presented at #ObesityWeek2026.
https://t.co/zCKNqFD23l
Michael Goran, PhD, highlighted the effects of early-life nutrition and ultraprocessed foods on neurodevelopment and #metabolic health at #ObesityWeek2026.
https://t.co/nwFFkAwSVI
In an oral session at #ObesityWeek2026, researchers presented study results on the efficacy of combination eloralintide and #tirzepatide in the treatment of overweight or #obesity and type 2 diabetes.
https://t.co/KFXFZPbbTr
Out of 40M+ with #diabetes, up to 95% have type 2:
1️⃣ 38M diagnosed (11M unaware)
2️⃣ 88% have overweight/obesity
3️⃣ Highest in AI/AN (15.7%) & Black adults (12.2%)
Biggest hurdle: screening or care access?
Full data: https://t.co/m5uAGBKIas
#Type2Diabetes
The conventional IDAA1c cutoff of 9 demonstrates poor sensitivity for identifying partial remission in pediatric patients with type 1 #diabetes and comorbid overweight or #obesity, suggesting that weight-stratified thresholds may be necessary.
https://t.co/18DVtzBXYq
Type 1 diabetes global & US trends:
🔹 ~9.5M cases globally (2.1M in US)
🔹 US mortality fell 2.1%–5.8% yearly (2000–2016)
🔹 Mortality risk remains 2–5x higher than non-diabetics
Full data: https://t.co/g6o3FGSRNN
#Diabetes#HealthStats
While survival rates for older adults with type 1 #diabetes are improving in high-income nations, profound global inequities in #insulin access and comorbidity management continue to hinder care in lower-income regions.
https://t.co/0bVSkpBZ6c
Higher long-term glycemic exposure and the presence of microvascular complications are significantly associated with an elevated risk for #sleep disturbances among older patients with type 1 #diabetes.
https://t.co/DqGOuqQdYE
3 #T1D stats every HCP should know:
🔹 Youth incidence rising up to 4.4%/yr in minority groups
🔹 Immunotherapy delays Stage 3 onset by ~2 yrs
🔹 ~5 in 1,000 US adults live with T1D[cite: 5]
Read the full factsheet here: https://t.co/xtTclJewop
#DiabetesCare#Endocrinology